The musician-turned-biotech-founder waiting to fundraise
Equity Podcast Recap
Published:
Duration: 29 min
Guests: Alo Black
Summary
The episode features Alo Black, a Grammy-nominated musician who transitioned into biotech entrepreneurship. It delves into his motivations, challenges in biotech funding, and the impact of AI on music and biotech.
What Happened
Alo Black, known for his music career, is also a biotech founder interested in cancer research and AI's impact on the music industry. He partnered with Dr. Gomika Urugamasoria from the University of Houston to develop a platform for creating molecules that bind with biomarkers, which can improve drug discovery.
Black initially invested in startups but found that leadership is critical for success. His transition to biotech was motivated by a desire for philanthropy, but he realized the industry requires significant funding and operational involvement. He has since hired a CEO to manage operations.
His interest in biotech was piqued during the COVID-19 pandemic, as he sought more preventative solutions. He started a company named Major Inc. to license intellectual property from universities, and it has since pivoted to focus on oncology with Peptoid as a subsidiary.
Biotech funding is challenging because it involves convincing investors and navigating regulatory hurdles. Black noted that biotech projects often take 10 years and hundreds of millions of dollars to bring a drug to market.
AI is transforming both biotech and music. In biotech, AI helps reduce drug discovery time by predicting molecular structures. In music, AI can replicate styles and sounds, but Black sees it as a tool for ideation rather than a replacement for human creativity.
Black is cautious about using AI in music, emphasizing the importance of oversight on content and fair compensation for artists. He believes AI can be a powerful tool but should not replace the purpose-driven nature of human creativity.
The economic implications of AI in music are significant. Black suggests that record labels may benefit the most by controlling the distribution of AI-generated music. He also sees potential for artists to use AI to enhance their creative processes.
Ultimately, Black believes that AI should be used to amplify human work, but it should not replace the meaningful journey of creation. He stresses the importance of balancing speed with the joy of the creative process.
Key Insights
- Alo Black transitioned from music to biotech to make a significant impact in oncology, partnering with Dr. Gomika Urugamasoria to develop molecules that bind to biomarkers.
- Biotech funding is complex, requiring significant investment and a solid leadership team. Black has experienced challenges in securing non-dilutive funding and emphasizes the importance of a strong scientific foundation.
- AI in biotech can streamline drug discovery by predicting molecular structures and reducing time and costs. However, AI has not yet significantly impacted Black's biotech research process.
- AI in music offers new possibilities for creation and ideation, but Black believes that human creativity and purpose must remain central. He is open to using AI for ideation but emphasizes the need for oversight and fair compensation.